{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:25:40Z","timestamp":1781483140157,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.060","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:32:21Z","timestamp":1729701141000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The contribution of addictovigilance data to the French medical cannabis experimentation"],"prefix":"10.1016","volume":"80","author":[{"given":"Emilie","family":"Bouquet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Jouanjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Batisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.060_bib0305","series-title":"Cannabis\u00a0\u2013\u00a0the current situation in Europe (European Drug Report 2024)","year":"2024"},{"key":"10.1016\/j.therap.2024.10.060_bib0310","series-title":"Mise en place de l\u2019exp\u00e9rimentation du cannabis m\u00e9dical","year":"2021"},{"key":"10.1016\/j.therap.2024.10.060_bib0315","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.060_bib0320","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1111\/bcp.14812","article-title":"Adverse events of recreational cannabis use reported to the French Addictovigilance Network (2012\u20132017)","volume":"87","author":"Bouquet","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0325","doi-asserted-by":"crossref","first-page":"e000638","DOI":"10.1161\/JAHA.113.000638","article-title":"Cannabis use: signal of increasing risk of serious cardiovascular disorders","volume":"3","author":"Jouanjus","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.therap.2024.10.060_bib0330","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1038\/s41598-022-19197-2","article-title":"Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020","volume":"12","author":"Bouquet","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.therap.2024.10.060_bib0335","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.3390\/ijms23105734","article-title":"Exploration of multiverse activities of endocannabinoids in biological systems","volume":"23","author":"Behl","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.therap.2024.10.060_bib0340","doi-asserted-by":"crossref","first-page":"412354","DOI":"10.1155\/2014\/412354","article-title":"Updates in reproduction coming from the endocannabinoid system","volume":"2014","author":"Meccariello","year":"2014","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.therap.2024.10.060_bib0345","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature20153","article-title":"The effects of \u03949-tetrahydrocannabinol on the dopamine system","volume":"539","author":"Bloomfield","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.therap.2024.10.060_bib0350","series-title":"Le point SINTES no 9","author":"Cherki","year":"2023"},{"key":"10.1016\/j.therap.2024.10.060_bib0355","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.forsciint.2017.01.007","article-title":"A study of cannabis potency in France over 25 years period (1992\u20132016)","volume":"272","author":"Dujourdy","year":"2017","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.therap.2024.10.060_bib0360","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/0269881120986393","article-title":"Cannabis based medecine and cannabis dependence: a critical review of issues and evidence","volume":"35","author":"Schlag","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0365","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: similarities and differences between siblings","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.therap.2024.10.060_bib0370","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0375","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.amjmed.2019.05.017","article-title":"Cannabis and cannabinoids: kinetics and interactions","volume":"132","author":"Foster","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.therap.2024.10.060_bib0380","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/can.2020.0083","article-title":"Cannabidiol interferes with establishment of \u03949-tetrahydrocannabinol-induced nausea through a 5-HT1A mechanism","volume":"7","author":"DeVuono","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.therap.2024.10.060_bib0385","first-page":"103","article-title":"Molecular Targets of the Phytocannabinoids: A Complex Picture","volume":"103","author":"Morales","year":"2017","journal-title":"Prog Chem Org Nat Prod"},{"key":"10.1016\/j.therap.2024.10.060_bib0390","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.euroneuro.2013.10.012","article-title":"Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience","volume":"24","author":"Foga\u00e7a","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0395","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.therap.2024.10.060_bib0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41401-018-0071-1","article-title":"Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation","volume":"40","author":"Bian","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.therap.2024.10.060_bib0405","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"De Almeida","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.therap.2024.10.060_bib0410","doi-asserted-by":"crossref","first-page":"114004","DOI":"10.1016\/j.bcp.2020.114004","article-title":"Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment","volume":"177","author":"Stark","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0415","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bcp.14973","article-title":"A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans","volume":"88","author":"Arout","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0420","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bph.15771","article-title":"Alternative pain management via endocannabinoids in the time of the opioid epidemic: peripheral neuromodulation and pharmacological interventions","volume":"180","author":"Lee","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0425","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bph.14627","article-title":"Cannabinoids and their actions: an update","volume":"176","author":"Alexander","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0430","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11910-015-0586-5","article-title":"Marijuana use in epilepsy: the myth and the reality","volume":"15","author":"Detyniecki","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.therap.2024.10.060_bib0435","first-page":"e3278","article-title":"Epilepsy and cannabis: a literature review","volume":"10","author":"Zaheer","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.therap.2024.10.060_bib0440","first-page":"15","article-title":"Le cannabis\u202f: addiction. Cons\u00e9quences aig\u00fces et chroniques","volume":"2","author":"Karila","year":"2017","journal-title":"Prat Sante Ment"},{"key":"10.1016\/j.therap.2024.10.060_bib0445","doi-asserted-by":"crossref","first-page":"e2686","DOI":"10.1055\/a-2145-7775","article-title":"Perinatal cannabis use and cannabis use during breastfeeding: the role of health care workers","volume":"41","author":"Bhatia","year":"2024","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.therap.2024.10.060_bib0450","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.therap.2024.10.060_bib0455","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-017-0663-0","article-title":"What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review","volume":"19","author":"Jouanjus","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.therap.2024.10.060_bib0460","doi-asserted-by":"crossref","first-page":"e000638","DOI":"10.1161\/JAHA.113.000638","article-title":"Cannabis use: signal of increasing risk of serious cardiovascular disorders","volume":"3","author":"Jouanjus","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.therap.2024.10.060_bib0465","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.drugalcdep.2017.09.038","article-title":"Cannabinoid hyperemesis syndrome: review of the literature and of cases reported to the French Addictovigilance Network","volume":"182","author":"Schreck","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.060_bib0470","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40264-022-01146-7","article-title":"Cannabinoid-related acute pancreatitis: an update from international literature and individual case safety reports","volume":"45","author":"Azam","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2024.10.060_bib0475","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40261-018-0679-4","article-title":"Identification of somatic disorders related to psychoactive drug use from an inpatient database in a French University Hospital","volume":"38","author":"Lafaurie","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.therap.2024.10.060_bib0480","series-title":"Les niveaux d\u2019usages des drogues illicites en France en 2017\u00a0\u2013\u00a0tendances 128","author":"Spilka","year":"2018"},{"key":"10.1016\/j.therap.2024.10.060_bib0485","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.therap.2022.10.003","article-title":"Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: insights of the annual cross sectional OPPIDUM survey","volume":"78","author":"Blayac","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.060_bib0490","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","article-title":"Cannabidiol adverse effects and toxicity","volume":"17","author":"Huestis","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0495","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.therap.2022.02.001","article-title":"Pharmacologie du cannabidiol\u00a0: points de vigilance, cons\u00e9quences et risques chez l\u2019homme","volume":"77","author":"Micallef","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.060_bib0500","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.therap.2023.05.003","article-title":"Cannabidiol and pharmacokinetics drug-drug interactions: pharmacological toolbox","volume":"79","author":"Lacroix","year":"2024","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.060_bib0505","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15287398009529853","article-title":"Cannabinoid-induced hormone changes in monkeys and rats","volume":"6","author":"Rosenkrantz","year":"1980","journal-title":"J Toxicol Environ Health"},{"key":"10.1016\/j.therap.2024.10.060_bib0510","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000471786","article-title":"High-dose cannabidiol induced hypotension after global hypoxia-ischemia in piglets","volume":"112","author":"Garberg","year":"2017","journal-title":"Neonatology"},{"key":"10.1016\/j.therap.2024.10.060_bib0515","series-title":"Mise \u00e0 jour des donn\u00e9es de s\u00e9curit\u00e9 du cannabidiol","year":"2018"},{"key":"10.1016\/j.therap.2024.10.060_bib0520","unstructured":"Product labeling EPIDYOLEX cannabidiol solution. Jazz Pharmaceuticals, Inc. Revised 03\/2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=8bf27097-4870-43fb-94f0-f3d0871d1eec&type=display. [Accessed 7 October 2024]."},{"key":"10.1016\/j.therap.2024.10.060_bib0525","first-page":"S71","article-title":"Cannabis m\u00e9dical\u00a0: retour sur l\u2019exp\u00e9rimentation fran\u00e7aise","volume":"35","author":"Auffret","year":"2023","journal-title":"Toxicol Anal Clin"},{"key":"10.1016\/j.therap.2024.10.060_bib0530","series-title":"Comit\u00e9 scientifique temporaire \u00ab\u00a0Suivi de l\u2019exp\u00e9rimentation fran\u00e7aise de l\u2019usage m\u00e9dical du cannabis\u00a0\u00bb. Compte-rendu","year":"2022"},{"key":"10.1016\/j.therap.2024.10.060_bib0535","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00213-021-06001-8","article-title":"Associations between cannabis use, cannabis use disorder, and mood disorders: longitudinal, genetic, and neurocognitive evidence","volume":"239","author":"Kuhns","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.therap.2024.10.060_bib0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/wps.20341","article-title":"Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis","volume":"15","author":"Murray","year":"2016","journal-title":"World Psychiatry"},{"key":"10.1016\/j.therap.2024.10.060_bib0545","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.pec.0000173349.38024.33","article-title":"Ataxia and shaking in a 2-year-old girl. Acute marijuana intoxication presenting as seizure","volume":"21","author":"Bonkowsky","year":"2005","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.therap.2024.10.060_bib0550","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/01.pec.0000204831.96139.52","article-title":"Marijuana intoxication presenting as seizure-comment","volume":"22","author":"Tilelli","year":"2006","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.therap.2024.10.060_bib0555","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.lpm.2009.03.020","article-title":"Accidental cannabis poisoning in children: experience of the Marseille poison center","volume":"38","author":"Spadari","year":"2009","journal-title":"Presse Med"},{"key":"10.1016\/j.therap.2024.10.060_bib0560","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2024.10.060_bib0565","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0024-3205(74)90361-0","article-title":"Delta9-tetrahydrocannabinol: subcortical spike bursts and motor manisfestaions in a fisher rat treated orally for 109 days","volume":"14","author":"Stadnicki","year":"1974","journal-title":"Life Sci"},{"key":"10.1016\/j.therap.2024.10.060_bib0570","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.982057","article-title":"Cannabinoid induced behavioral convulsions in rabbits","volume":"194","author":"Martin","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.therap.2024.10.060_bib0575","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14737175.2021.1935879","article-title":"Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years accumulated evidence from clinical trials","volume":"21","author":"Prieto Gonz\u00e1lez","year":"2021","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.therap.2024.10.060_bib0580","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/07067437211060597","article-title":"Substance use disorders and psychoactive drug poisoning in medically authorized cannabis patients: longitudinal cohort study","volume":"67","author":"Zongo","year":"2022","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.therap.2024.10.060_bib0585","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.addbeh.2019.02.003","article-title":"Prevalence and correlates of medical cannabis patients\u2019 use of cannabis for recreational purposes","volume":"93","author":"Morean","year":"2019","journal-title":"Addict Behav"},{"key":"10.1016\/j.therap.2024.10.060_bib0590","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/npr2.12183","article-title":"An initial analysis of the UK Medical Cannabis Registry: outcomes analysis of first 129 patients","volume":"41","author":"Erridge","year":"2021","journal-title":"Neuropsychopharmacol Rep"},{"key":"10.1016\/j.therap.2024.10.060_bib0595","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/17512433.2023.2183841","article-title":"An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry","volume":"16","author":"Olsson","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.060_bib0600","doi-asserted-by":"crossref","first-page":"107667","DOI":"10.1016\/j.addbeh.2023.107667","article-title":"Prevalence of cannabis use disorder among individuals using medical cannabis at admission to inpatient treatment for substance use disorders","volume":"142","author":"Gendy","year":"2023","journal-title":"Addict Behav"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:34:52Z","timestamp":1744202092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001768"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.060","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The contribution of addictovigilance data to the French medical cannabis experimentation","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}